• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

    9/28/21 8:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations. Dr. Edwards will join the senior leadership team and be responsible for technical development, manufacturing, quality and supply chain operations.

    "We are excited to welcome Karen-Leigh to the Ocular team," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "With experience across multiple disciplines at several leading pharmaceutical companies, Karen-Leigh's proven ability to develop supply chains and global manufacturing strategies will be key as we seek to grow and maximize the value of our leading ophthalmic franchise."

    Dr. Edwards has over 20 years of experience building high-performance, global enterprise-wide manufacturing operations as well as CMC and product lifecycle management strategies. Prior to joining Ocular, Dr. Edwards held multiple positions of increasing responsibilities at Alexion Pharmaceuticals. Most recently, she served as the Head of External Manufacturing and Operations and built a high-performance global manufacturing organization across the U.S., Europe and Asia, with the agility and flexibility required to deliver Alexion's growing commercial portfolio. Prior to Alexion, Dr. Edwards held multiple positions at Biogen, Inc., including roles in portfolio management, pharmaceutical development, product quality, global supply chain and contract manufacturing. She holds an M.B.A. from MIT Sloan School of Management, a Ph.D. in Bioinorganic Chemistry from the University of Kansas, an M.Sc. in Inorganic Chemistry from the University of London, and B.Sc. in Chemistry/Analytical Chemistry from the University of the West Indies.

    "The impressive launch and growth of DEXTENZA® along with the continued development of Ocular's rich pipeline of novel ophthalmic products, many of which are approaching late-stage clinical development, make this an exciting time to join the team," said Dr. Edwards. "I look forward to working with the technical operations team as we endeavor to build a world-class manufacturing organization to support the Company's growth strategies."

    About Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application for DEXTENZA to include an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

    Forward Looking Statements

    Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the conduct of post-approval studies of and compliance with related labeling requirements for DEXTENZA and ReSure Sealant; the development and regulatory status of the Company's product candidates, such as the Company's development of and prospects for approvability of DEXTENZA for additional indications including the PDUFA target action date scheduled for October 18, 2021 for allergic conjunctivitis, OTX-CSI for the chronic treatment of dry eye disease, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, and OTX-TKI for the treatment of retinal diseases including wet AMD; the ongoing development of the Company's extended-delivery hydrogel depot technology; the size of potential markets for our product candidates; the potential utility of any of the Company's product candidates; the potential benefits and future operations of Company collaborations, including any potential future costs or payments thereunder; projected net product revenue, in-market sales and other financial and operational metrics of DEXTENZA and ReSure Sealant; potential market sizes for indications targeted by the Company's product candidates, if approved; the expected impact of the COVID-19 pandemic on the Company and its operations; the sufficiency of the Company's cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company's ability to enter into and perform its obligations under collaborations and the performance of its collaborators under such collaborations, the Company's scientific approach and general development progress, the availability or commercial potential of the Company's product candidates, the Company's ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company's existing indebtedness, the ability of the Company's creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company's and relevant regulatory authorities' operations, any additional financing needs and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005387/en/

    Get the next $OCUL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    9/15/2025$21.00Buy
    Chardan Capital Markets
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    More analyst ratings

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Ocular Therapeutix with a new price target

    Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00

    9/15/25 8:09:22 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Ocular Therapeutix

    William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

    4/8/25 9:29:59 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

    RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

    3/18/25 7:53:57 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

    BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular", the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about October 1, 2025, subject to the satisfaction of customary closing conditions. BofA S

    9/30/25 7:08:41 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

    SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient selection strategy, trial design, and potential SOL-1 success could drive confidence in SOL-R outcomes; topline data on track for 1H 2027 Will showcase planned HELIOS-2 and HELIOS-3 registrational trials to evaluate AXPAXLI in non-proliferative diabetic retinopathy (NPDR) using novel primary endpoint, aligned with FDA in HELIOS-2 Special Protocol Assessment (SPA) agreement To outline SOL-X open label extension program and AXPAXLI's potential to improve lon

    9/30/25 6:21:07 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Host Investor Day on September 30, 2025

    Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease experts Dr. Arshad M. Khanani MD, MA, FASRS; Professor Adnan Tufail, MBBS, MD, FRCOphth; Dr. Eleonora Lad, MD, PhD; and Dr. Patricio G. Schlottmann, MD The live event will take place in New York City on September 30, 2025, at 2:00 PM ET BEDFORD, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, will host an Investor Day on Tuesday, September 30, 2025, in New Y

    9/8/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $OCUL
    SEC Filings

    View All

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/27/24 4:43:51 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    12/18/23 4:52:33 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Ocular Therapeutix Inc.

    424B5 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    9/30/25 4:01:32 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    9/30/25 8:21:01 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix Inc. filed SEC Form 8-K: Other Events

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    9/30/25 6:32:59 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Dugel Pravin gifted 49,754 shares and received a gift of 49,754 shares, decreasing direct ownership by 2% to 3,177,490 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    9/11/25 4:06:45 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Notman Donald sold $13,250 worth of shares (1,066 units at $12.43), decreasing direct ownership by 0.34% to 308,807 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    9/4/25 4:50:06 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $36,252 worth of shares (3,011 units at $12.04), decreasing direct ownership by 1% to 204,093 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    8/27/25 6:44:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 9:37:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/12/24 4:49:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix® to Host Investor Day on June 13, 2024

    Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

    6/5/24 7:30:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports First Quarter 2024 Results

    Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

    5/7/24 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

    Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

    4/16/24 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

    Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance of $391.1 million as of June 30, 2025, with expected runway into 2028, well beyond anticipated topline data for SOL-1 and SOL-R BEDFORD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Thera

    8/5/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

    BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix webs

    7/29/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

    BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

    4/28/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care